Evidence should answer the adoption question, not only the regulatory question
Early medtech companies often think about evidence through a regulatory lens first. That is necessary, but not sufficient. Commercial adoption usually requires a broader evidentiary story that speaks to clinicians, administrators, payers, investors, strategic partners, and KOLs.
The core questions
A practical evidence roadmap should clarify:
- What clinical behavior needs to change?
- Which stakeholder must believe the evidence?
- Which endpoint demonstrates value most directly?
- What evidence is required for credibility versus formal approval?
- What data would reduce investor, clinician, or buyer skepticism?
- Which study designs are feasible at the company’s current stage?
MedTex perspective
The strongest evidence strategies are built backward from adoption. The goal is not merely to collect data, but to create a staged, credible evidence narrative that supports clinical trust, investor confidence, and commercial execution.